171 related articles for article (PubMed ID: 35461328)
1. MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
Pang Z; Dong X; Deng H; Wang C; Liao X; Liao C; Liao Y; Tian W; Cheng J; Chen G; Yi H; Huang L
Oncogene; 2022 May; 41(22):3064-3078. PubMed ID: 35461328
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer.
Campos LC; Silva JO; Santos FS; Araújo MR; Lavalle GE; Ferreira E; Cassali GD
J Vet Diagn Invest; 2015 Jul; 27(4):531-5. PubMed ID: 26179096
[TBL] [Abstract][Full Text] [Related]
3. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
[TBL] [Abstract][Full Text] [Related]
4. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
5. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
6. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland.
Schroeder JA; Thompson MC; Gardner MM; Gendler SJ
J Biol Chem; 2001 Apr; 276(16):13057-64. PubMed ID: 11278868
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of MUC1 in mammary tumors generated in a double-transgenic mouse expressing human MUC1 cDNA, under the control of 1.4-kb 5' MUC1 promoter sequence and the middle T oncogene, expressed from the MMTV promoter.
Graham RA; Morris JR; Cohen EP; Taylor-Papadimitriou J
Int J Cancer; 2001 May; 92(3):382-7. PubMed ID: 11291075
[TBL] [Abstract][Full Text] [Related]
8. The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin.
Li Y; Yi H; Yao Y; Liao X; Xie Y; Yang J; Yan Z; Wang L; Lu S; Kuang Y; Gu M; Fei J; Wang Z; Huang L
PLoS One; 2011 Apr; 6(4):e19102. PubMed ID: 21533058
[TBL] [Abstract][Full Text] [Related]
9. MUC1 can interact with adenomatous polyposis coli in breast cancer.
Hattrup CL; Fernandez-Rodriguez J; Schroeder JA; Hansson GC; Gendler SJ
Biochem Biophys Res Commun; 2004 Apr; 316(2):364-9. PubMed ID: 15020226
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
Alam M; Rajabi H; Ahmad R; Jin C; Kufe D
Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886
[TBL] [Abstract][Full Text] [Related]
11. Paget's disease of the nipple in a Her2-positive breast cancer xenograft model.
Drews-Elger K; Sandoval-Leon AC; Ergonul AB; Jegg AM; Gomez-Fernandez C; Miller PC; El-Ashry D; Lippman ME
Breast Cancer Res Treat; 2020 Feb; 179(3):577-584. PubMed ID: 31720992
[TBL] [Abstract][Full Text] [Related]
12. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.
Gheybi E; Amani J; Salmanian AH; Mashayekhi F; Khodi S
Tumour Biol; 2014 Nov; 35(11):11489-97. PubMed ID: 25128064
[TBL] [Abstract][Full Text] [Related]
13. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.
Khodarev N; Ahmad R; Rajabi H; Pitroda S; Kufe T; McClary C; Joshi MD; MacDermed D; Weichselbaum R; Kufe D
Oncogene; 2010 Feb; 29(6):920-9. PubMed ID: 19915608
[TBL] [Abstract][Full Text] [Related]
14. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.
Kharbanda A; Rajabi H; Jin C; Raina D; Kufe D
Mol Cancer Res; 2013 Jul; 11(7):714-23. PubMed ID: 23538857
[TBL] [Abstract][Full Text] [Related]
16. Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
Goyette MA; Stevens LE; DePinho CR; Seehawer M; Nishida J; Li Z; Wilde CM; Li R; Qiu X; Pyke AL; Zhao S; Lim K; Tender GS; Northey JJ; Riley NM; Long HW; Bertozzi CR; Weaver VM; Polyak K
Proc Natl Acad Sci U S A; 2024 May; 121(20):e2322688121. PubMed ID: 38709925
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor alpha dependent cancer progression is modulated by Muc1.
Pochampalli MR; Bitler BG; Schroeder JA
Cancer Res; 2007 Jul; 67(14):6591-8. PubMed ID: 17638868
[TBL] [Abstract][Full Text] [Related]
18. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
[TBL] [Abstract][Full Text] [Related]
19. Differential gene expression profiling of human epidermal growth factor receptor 2-overexpressing mammary tumor.
Wang Y; Peng H; Zhong Y; Li D; Tang M; Ding X; Zhang J
Acta Biochim Biophys Sin (Shanghai); 2008 May; 40(5):397-405. PubMed ID: 18465025
[TBL] [Abstract][Full Text] [Related]
20. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway.
Woo JK; Choi Y; Oh SH; Jeong JH; Choi DH; Seo HS; Kim CW
Oncogene; 2012 Apr; 31(17):2187-98. PubMed ID: 21927028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
